Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16766
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPavlakis, Nick-
dc.contributor.authorSjoquist, Katrin M-
dc.contributor.authorMartin, Andrew J-
dc.contributor.authorTsobanis, Eric-
dc.contributor.authorYip, Sonia-
dc.contributor.authorKang, Yoon-Koo-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorAlcindor, Thierry-
dc.contributor.authorO’Callaghan, Christopher J-
dc.contributor.authorBurnell, Margot J-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorRha, Sun Young-
dc.contributor.authorLee, Jeeyun-
dc.contributor.authorCho, Jae-Yong-
dc.contributor.authorLipton, Lara R-
dc.contributor.authorWong, Mark-
dc.contributor.authorStrickland, Andrew-
dc.contributor.authorKim, Jin Won-
dc.contributor.authorZalcberg, John R-
dc.contributor.authorSimes, John-
dc.contributor.authorGoldstein, David-
dc.date2016-06-20-
dc.date.accessioned2017-08-03T05:59:30Z-
dc.date.available2017-08-03T05:59:30Z-
dc.date.issued2016-08-10-
dc.identifier.citationJournal of Clinical Oncology 2016; 34(23): 2728-2735en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16766-
dc.description.abstractPURPOSE: We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. PATIENTS AND METHODS: We conducted an international (Australia and New Zealand, South Korea, and Canada) randomized phase II trial in which patients were randomly assigned at a two-to-one ratio and stratified by lines of prior chemotherapy for advanced disease (one v two) and region. Eligible patients received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 of each 28-day cycle until disease progression or prohibitive adverse events occurred. The primary end point was progression-free survival (PFS). Final analysis included data to December 31, 2014. RESULTS: A total of 152 patients were randomly assigned from November 7, 2012, to February 25, 2014, yielding 147 evaluable patients (regorafenib, n = 97; placebo, n = 50). Baseline characteristics were balanced. Median PFS significantly differed between groups (regorafenib, 2.6 months; 95% CI, 1.8 to 3.1 and placebo, 0.9 months; 95% CI, 0.9 to 0.9; hazard ratio [HR], 0.40; 95% CI, 0.28 to 0.59; P < .001). The effect was greater in South Korea than in Australia, New Zealand, and Canada combined (HR, 0.12 v 0.61; interaction P < .001) but consistent across age, neutrophil-to-lymphocyte ratio, primary site, lines of chemotherapy, peritoneal metastasis presence, number of metastatic sites, and plasma vascular endothelial growth factor A. A survival trend in favor of regorafenib was seen (median, 5.8 months; 95% CI, 4.4 to 6.8 v 4.5 months; 95% CI, 3.4 to 5.2; HR, 0.74; P = .147). Twenty-nine patients assigned to placebo received open-label regorafenib after disease progression. Regorafenib toxicity was similar to that previously reported. CONCLUSION: In this phase II trial, regorafenib was effective in prolonging PFS in refractory advanced gastric adenocarcinoma. Regional differences were found, but regorafenib was effective in both regional groups. A phase III trial is planned.en_US
dc.subjectAdenocarcinoma/drug therapyen_US
dc.subjectAntineoplastic agents/therapeutic useen_US
dc.subjectPhenylurea compounds/therapeutic useen_US
dc.subjectPyridines/therapeutic useen_US
dc.subjectStomach neoplasms/drug therapyen_US
dc.titleRegorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II triaen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Clinical Oncologyen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationRoyal North Shore Hospital, University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationCancer Care Centre, St George Hospital, NSW, Australiaen_US
dc.identifier.affiliationSydney Catalyst Translational Cancer Research Centre, NSW, Australiaen_US
dc.identifier.affiliationWestmead Hospital, NSW, Australiaen_US
dc.identifier.affiliationPrince of Wales Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationWestern Health, Victoria, Australiaen_US
dc.identifier.affiliationMonash Medical Centre, Victoria, Australiaen_US
dc.identifier.affiliationPeter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationAsan Medical Center, University of Ulsan College of Medicine, South Koreaen_US
dc.identifier.affiliationSeoul National University Hospital, Seoul, South Koreaen_US
dc.identifier.affiliationYonsei University College of Medicine, Seoul, South Koreaen_US
dc.identifier.affiliationSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Koreaen_US
dc.identifier.affiliationGangnam Severance Cancer Hospital, Yonsei University College of Medicine, Seoul, South Koreaen_US
dc.identifier.affiliationSeoul National University Bundang Hospital, Seongnam, South Koreaen_US
dc.identifier.affiliationMcGill University Health Centre, Montreal, Quebec, Canadaen_US
dc.identifier.affiliationNational Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canadaen_US
dc.identifier.affiliationSaint John Regional Hospital, Saint John, New Brunswick, Canadaen_US
dc.type.studyortrialClinical Trialen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27325864en_US
dc.identifier.doi10.1200/JCO.2015.65.1901en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherTebbutt, Niall C
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Jun 14, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.